Get the app
US › Healthcare

NextCure  Inc (NXTC)

US · Healthcare · Biotechnology

$6.24-9.30%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-14.9M
EPS
$-1.84
EPS estimate
$-1.98

EPS came in at -1.84 against a street estimate of -1.98 — a beat of 7.1%.

Key statistics

Market cap
$30.1M
Forward P/E
0.0
P/B
1.82
Book value
$2.99
EPS (TTM)
$-8.71
52-week high
$15.74
52-week low
$1.55
50-day MA
$6.35
200-day MA
$8.31
Beta
1.35

Analyst view

Analysts rate NextCure  Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $20.00.

Shareholding

Insiders
8.64%
Institutions
52.75%

Largest institutional holders

FundStake
Ikarian Capital, LLC6.30%
Adage Capital Partners Gp LLC6.06%
Sofinnova Ventures4.86%
Renaissance Technologies Corp3.74%
Vanguard Capital Management, LLC3.43%
Millennium Management LLC1.93%
BOOTHBAY FUND MANAGEMENT, LLC1.85%
Squadron Capital Management LLC1.41%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for NextCure  Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.